(NASDAQ: CTKB) Cytek Biosciences's forecast annual revenue growth rate of 8.99% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 6.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 8.88%.
Cytek Biosciences's revenue in 2024 is $201,210,000.On average, 3 Wall Street analysts forecast CTKB's revenue for 2024 to be $26,465,815,184, with the lowest CTKB revenue forecast at $26,405,016,574, and the highest CTKB revenue forecast at $26,586,510,730. On average, 3 Wall Street analysts forecast CTKB's revenue for 2025 to be $29,618,712,583, with the lowest CTKB revenue forecast at $28,119,357,036, and the highest CTKB revenue forecast at $30,407,033,541.
In 2026, CTKB is forecast to generate $33,712,829,139 in revenue, with the lowest revenue forecast at $31,726,054,228 and the highest revenue forecast at $34,779,123,401.